141 related articles for article (PubMed ID: 17244110)
1. Comments on plasma parathyroid hormone levels and their relationship to bone histopathology among patients undergoing dialysis.
Goodman WG
Semin Dial; 2007; 20(1):1-4. PubMed ID: 17244110
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Bone and bone related biochemical examinations. Hormone and hormone related substances. Parathyroid hormone].
Tanaka M; Fukagawa M
Clin Calcium; 2006 Jun; 16(6):927-34. PubMed ID: 16751687
[TBL] [Abstract][Full Text] [Related]
4. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study.
Melamed ML; Eustace JA; Plantinga LC; Jaar BG; Fink NE; Parekh RS; Coresh J; Yang Z; Cantor T; Powe NR
Nephrol Dial Transplant; 2008 May; 23(5):1650-8. PubMed ID: 18065788
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management.
Cantor T
Semin Dial; 2005; 18(5):359-64. PubMed ID: 16191171
[TBL] [Abstract][Full Text] [Related]
6. Immunoassays for the detection of parathyroid hormone.
Jüppner H; Potts JT
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N81-6. PubMed ID: 12412782
[TBL] [Abstract][Full Text] [Related]
7. Critical issues of PTH assays in CKD.
Komaba H; Goto S; Fukagawa M
Bone; 2009 Apr; 44(4):666-70. PubMed ID: 19159701
[TBL] [Abstract][Full Text] [Related]
8. An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease.
Savoca R; Bock A; Kraenzlin ME; Schmid HR; Huber AR
Clin Chim Acta; 2004 May; 343(1-2):167-71. PubMed ID: 15115690
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of PTH (1-84) and PTH (7-84) in patients with predialysis chronic renal failure in relation to bone metabolism markers].
Tsuchida T; Ishimura E; Hirowatari K; Matsumoto N; Jono S; Miki T; Inaba M; Nishizawa Y
Clin Calcium; 2005 Sep; 15 Suppl 1():156-60; discussion 160. PubMed ID: 16272650
[TBL] [Abstract][Full Text] [Related]
10. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
[TBL] [Abstract][Full Text] [Related]
11. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
12. [PTH and bone metabolism in chronic dialysis patients].
Fukagawa M; Kazama J; Shigematsu T
Rinsho Byori; 2001 Mar; 49(3):236-8. PubMed ID: 11307321
[TBL] [Abstract][Full Text] [Related]
13. [Parathormone and chronic kidney disease].
Bacchetta J; Jolivot A; Souberbielle JC; Charrié A; Guebre F; Chauvet C; Fouque D
Nephrol Ther; 2007 Jul; 3(4):133-8. PubMed ID: 17658439
[TBL] [Abstract][Full Text] [Related]
14. Relationship between serum parathyroid hormone and trace elements (serum zinc and magnesium) in hemodialyzed chronic renal failure children.
El Tayeb AA; Abd El-Mottaleb NA; Abdel Aziz EA
Biol Trace Elem Res; 2009 May; 128(2):128-34. PubMed ID: 18972069
[TBL] [Abstract][Full Text] [Related]
15. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
[TBL] [Abstract][Full Text] [Related]
16. Differences between serum and plasma for intact parathyroid hormone measurement in patients with chronic renal failure in routine clinical practice.
Twomey PJ; Whitlock T; Pledger DR
J Clin Pathol; 2005 Sep; 58(9):1000-1. PubMed ID: 16126890
[TBL] [Abstract][Full Text] [Related]
17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
18. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
19. Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism.
Kazama JJ; Omori K; Yamamoto S; Ito Y; Maruyama H; Narita I; Gejyo F; Iwasaki Y; Fukagawa M
Ther Apher Dial; 2006 Jun; 10(3):262-6. PubMed ID: 16817791
[TBL] [Abstract][Full Text] [Related]
20. Serum level of intact parathyroid hormone and other markers of bone metabolism in dialyzed patients.
Grzegorzewska AE; Młot-Michalska M
Adv Perit Dial; 2007; 23():162-5. PubMed ID: 17886625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
